The probability of obtaining a tumor in a carcinogenesis bioassay depends mainly on the time on test and on the dose of carcinogen used. There i s very limited data on the shape of this surface or reliable data on dose-response or time on test-response relationships. Ullrich's data on tumor induction by low dose radiation shows a variety of shapes of curve depending on the tissue chosen for investigation. As radiation probably does not concern the processes involved in xenobiotic metabolism, these observations clearly demonstrate that factors other than metabolism are important. An attempt is made to discuss the shape of the dose-response curve in relation to a number of factors including the background incidence of tumors in a tissue, mechanisms of "nongenotoxic" or toxicity-related carcinogenesis, and xenobiotic activation of carcinogens.
INTRODUCTION
At its simplest, cuncer is a disease of multicellular organisms in which some cells of one constituent population have undergone changes that permit this altered subpopulation to grow in a relatively less controlled fashion to an extent that is eventually incompatible with the continued survival of the organism. Such an attempt at definition tells us that there are at least two stages in cancer induction: (i) a stage in which individual cells are altered and (ii) a survival competition between these altered cells and the unaltered cells. That is, the probability of a treatment leading to cancer will depend on both the dose level and the potency of the treatment in inducing cellular change and on the effect of the treatment on the survival competition. The treatment may influence the cells involved in the survival competition directly, * Presented at tlic Tliird lntcrnational Symposium of the Sociely of Toxicologic Pathologists. hiay 13-15, 1984, Arlington. \'A. or indirectly through the modification of body-wide control systems such as hormonal production or immunologic competence.
Overall, these simplified definitions imply that the lower regions of the dose-response curve in carcinogenesis will depend mainly on factors related to the change in the cell population and will be dependent on the metabolism of procardnogens, the ability of activated metabolites to interact with the critical target which appears to be DNA, and DNA replication or repair ( Fig. 1) . At higher dose levels such as are usually employed in cancer bioassays, this already complex process will be overlaid by toxic effects of the agent acting directly on the survival competition or h d irectly on systems in the whole organism.
DOSE RESPONSE I N CARCINOCENESIS
The above considerations promise a lack of uniformity in dose-response curves for different carcinogenic agents. Our data base is, unfortunately, severely limited and unlikely to be markedly expanded because adequate 120 CLAYSON TOXICOLOGIC PATHOLOGY dose-response curves require large numbers of animals and are very costly to perform. Most dose-response curves do not contain as adequate information as is desirable. The time it takes for tumors to arise is an important aspect in the induction of cancer (26) but, because it involves serial killings of large numbers of test animals and consequent increase in costs, it is only infrequently inves-tigated. The ED01 experiment carried out by the United States National Center for Toxicological Research is undoubtedly the prime example of a complete dose-response investigation, but it involved over 22,000 mice and cost many millions of dollars (27) . The diverse shapes of the dose-response curve can be illustrated by the studies carried out by Ullrich and his colleagues on the induction of CF1 mouse tumors by y-radiation (30-33). The dose-response curves (Fig. 2) clearly illustrate the lack of uniformity of response. The variance does not appear to be a statistical artifact, as adequate numbers of animals were used but represents real differences in the response of different tissues to y-radiation. Ullrich et a1 (31) comment that no single mathematical formula is capable of fitting all these curves. From the viewpoint of the present discussion, it should be-realized that the explanation of the effects of whole body radiation on each tissue will require in-depth consideration of the multiple factors governing the induction of cancer in the whole animal and in each specific tissue, an awesome academic exercise. Specifically, the shapes of the dose-response curves for yrays are most unlikely to be predicated by changes in xenobiotic metabolism as y-radiation is believed to act directly on the genome. Xenobiotic metabolic activation can thus be seen to be only one factor in determining the shape of a particular dose-response curve in carcinogenesis.
The ED01 experiment involved feeding N-2-fluorenylacetamide (FAA) to over 22,000 BALB/C female mice at a variety of dose levels, ranging from 0 to 150 ppm, in the diet for up to 33 months. Serial killings were made at 9,12,14,15,16,17, and 24 months and the terminal kill at 33 months. Tumorigenesis was examined in both bladder and liver with discordant results (Fig. 3) . The dose-response curve for the liver was near-linear in the studied dose range, that for the bladder was steeply curved with an apparent threshold at about 60 ppm FAA in the diet (27) . Both liver and bladder epithelial cells (18, 21) are able to activate FAA metabolically so that any attempt to explain the differences between these curves in terms of absolute differences in metabolic activation would require the liver-and bladder-metabolizing enzymes to exhibit very different properties, a suggestion for which evidence is, to the best' of my knowledge, nonexistent.
A different and speculative interpretation of the oral FAA-induced dose-response curves depends on the fact that while there is a very low background incidence of bladder tumors in the controls, liver tumors in BALB/C mice are present in over 30% of untreated female mice by 33 months. Provided that the background tumors of the liver arise in a similar manner to induced tumors, it is to be expected that they will be accompanied by initiated cells or foci of cells that have not quite made it to the stage of frank cancer. These foci might be swept forward in time by a much less complex process than the complete induction of cancer ( Fig. 4 ) (10). If, in fact, this sweeping forward in time reflects only a single action of FAA on the mouse liver, it may be understood why a linear dose-response curve has been obtained. Another example of a roughly linear dose-response curve was obtained by Thorpe and Walker (28) in both male and female mice there was about a 20% incidence of background tumors and so far as the .limited data permits, the dose-response curve appears to be near-linear. Considera tion of (1,1,1 -trichloro-2,2bis(p-chloropheny1)ethane (DDT) however illustrates the difficulties in making generalizations of any sort in this area. Data presented by Tomatis et a1 (29) is not incompatible with a linear dose-response curve in female CF1 mice ( Fig. 7) . It is however difficult to reconcile the data in male mice with the proposed generalization unless it is assumed that the male environment, even at low levels of DDT is highly toxic to initiated cells or foci.
The final examples of dose-response curves to be considered are those in which it appears to be necessary to administer a considerable amount of the carcinogen over the whole of the animal's life span to obtain tumors. Sodium trinitriloacetate (NTA) provides an example insofar as it induces bladder cancer at dietary levels of over 1% in the food in rats ( Fig. 8 ) (1). Anderson (2, 3) suggested that nitrilotriacetate acts as a chelating agent and has demonstrated its effectiveness in removing zinc ions from the bladder tissue. He suggests that until it reaches a sufficient urinary level, the removaI of zinc by cheIation is not an overtly toxic reaction. Above this level, however, sufficient zinc ion is removed to produce an adverse reaction that eventually leads to cancer. For instance, it is pos- sible that removal of the zinc ion leads to an impairment of the asymmetric membrane that provides the ionic and water-resistant permeability barrier (12) . In other cases, such as jnduced cytotoxic chemical damage or physical damage such impairment leads to a proliferative response (g), a condition favorable to the development of tumors.
In order to emphasize further the lack of uniformity of dose-response curves even for agents that appear to induce similar effects, it is instructive to compare the dose-response curve for NTA with that of the rat bladder cancer-inducer saccharin (Fig. 9 ). These curves are quite different. While it may be speculated that NTA may impair the permeability barrier as its primary effect, saccharin is normally unable to cross this barrier (24), but when it is able to do so may induce cancer by a different, possibly nonthresholded mechanism (8).
Consideration of these few carcinogenesis dose-response curves tells us a number of important things. First, there is no uniformity in the carcinogenesis dose-response curve between different types of agents; second, use of mathematical models in risk assessment for obtaining a virtually safe dose for humans is still a very dubious procedure despite the claims of the developers of the current series of models that they are each consonant with what is known about carcinogenesis mechanisms; and third, that it is unlikely that better risk estimates will be obtained until more is known about the course of events by which a chemical induces cancer.
MECHANISMS OF CARCINOCENESIS AND METABOLISM
From the mechanistic viewpoint it is currently recognized that in several tissues, chemical carcinogenesis may be divided into a rapid and relatively irreversible primary stage called "initiation" followed by a partially reversible and slow developmental phase called "promotion." (5-7,23) . From Figure 1 , the detailed events of the initiation phase appear to be metabolic activation (where necessary), delivery of the active metabolite to its critical target (probably DNA) and the interaction of the active metabolite with its target. The DNA-carcinogen adduct undergoes fixation to produce a mutated Cell as a result of DNA and cell replication or is removed by appropriate DNA repair processes (21). The recent and exciting identification of oncogenes promises a much clearer understanding of the actual critical sites of carcinogen-DNA interaction that will lead to tumor formation.
Most, if not all, multicellular organisms possess a variety of enzymes that are capable of transforming xenobiotics to metabolic forms more easily excreted from the organism. These metabolic enzymes are found, for example, in Drosophila, fish, and mammals. The actions of these enzymes may be classified into two stages: phase 1 enzymes convert the xenobiotic to a form that is capable of conjugation by, for example, inserting a hydroxyl group in the molecule; phase 2 enzymes conjugate this newly inserted or pre-existing hydroxyl, amino, thiol, or acid group with, for example, glucuronic acid, sulfate ion, or mercapturic acid. The function of these metabolic enzymes is thus to protect the organism against the accumulation of toxic levels of xenobiotics.
With many carcinogens the protective role of these metabolic enzymes is perverted and leads to the conversion of the procarcinogen to a highly reactive positively charged form known as an electrophile. This will interact with any group of atoms in the organism that possesses an excess of electrons including specific sites on the genetic material, DNA molecules at the site of the DNA is a major determinant of the overall probability of obtaining a tumor, their measurement is very difficult. Instead, scientists have relied on either attempted correlations of tumor incidence with gross changes in metabolism or with measurements of the level of DNA-carcinogen adduct formation (17, 18) . Both the activation and detoxification of a carcinogen vary with the age of the animal and may be modified by a variety of factors. The overall effect of such factors depends ultimately on the proportion of a Carcinogen converted to its active form. The position is further complicated by the fact that each cell type possesses some enzymes capable of metabolic activation and an effect in, one tissue may not be reflected in another. Two examples will make this point clear. Dimethylnitrosamine is highly toxic to rat liver and induces kidney cancer in rats after a single large dose. Liver toxicity may be reduced by feeding a very low (zero) protein diet for 10 days and a 100% incidence of kidney tumors thereby obtained by administering a higher level of the carcinogen (19, 20) . Similarly, male rats develop a much higher incidence of liver cancer than female rats when FAA is fed in the diet. This has been demonstrated to be due to the dependence of the enzyme responsible for the ultimate activation stage, the transfer of sulfate from phosphoadenosine phosphosulfate to N-hydroxy-N-2-fluorenylacetamide, for a male hormonal environment (21). It is noteworthy that while this sulfotransferase seems critical to the activation of FAA in rat liver, the enzyme has not been demonstrated in either the mammary or acoustic glands that are targets of FAA tumorigenesis, thus suggesting that there are multiple reactive endpoints for FAA, a further complexity in an already complex system (15) . It is to be noted that nutrition and hormone levels, the relevant factors in these two examples, also affect other parts of the carcinogenic process, such as the tumor developmental stage.
Overall, the most important and most studied group of agents that may modify carcinogenic action 'are the enzyme-inducing agents that were discovered (11) in an investigation of why feeding 3-methylcholanthrene with an aminoazodye inhibited the dye-induced formation of liver cancers in rats (25) . Enzyme-inducing agents, which may be carcinogens or noncarcinogens, lead to increased levels of specific metabolic enzymes within cells. Individual inducing agents may act on the P4s, or the P448 cytochrome complex central to enzymic metabolizing systems and may therefore differ in their overall effects on the metabolism of specific carcinogens. Their utility as carcinogenesis inhibitors has been reviewed by .
These few examples serve to demonstrate that factors modifying metabolism may affect the quantitative pattern of the dose-response curve. Some factors may decrease the level of active metabolite and tumors formed when applied with the carcinogen but may have an opposite effect if applied during the competition stage of carcinogenesis. Phenobarbital is an enzyme-inducing agent and when fed coincidentally with FAA inhibits tumorigenesis. If, however, the animals are fed phenobarbital after a limited amount of FAA the incidence of tumors is increased (22) .
ADDITIONAL FACTORS MODIFYING DOSE RESPONSE
These experiments should alert the scientific community to the fact that a wide vari-Vol. 13, No. 2, 1985 DOSES IN EXPERIMENTAL CARCINOGENESIS   125 ety of influences ranging from these affecting the internal mechanisms of the body such as hormonal levels to those affecting immune reactions or metabolism may greatly influence the quantitative, and possibly the qualitative, response of an animal to a carcinogen. That is to say, these factors have the capability to move the dose-response curve backward or forward in time and up or down the dose-response scale. This is a most disturbing state of affairs because of society's reliance on animal studies to protect humans from cancer induction. It is possible to confine laboratory animals to a minimum of variable secondary factors by controlling their diet, their drinking water, and their environment. People know no such limitations and, especially in a Western Society, enjoy a wide range of foodstuffs, variously contaminated drinking water, sodas and more potent beverages, and an environment that varies from the workbench to the nightclub. We know all too little about the effects of secondary chemicals in carcinogenesis. We must therefore be exceedingly conservative when we attempt to translate quantitative aspects of carcinogenesis including considerations such as dose-response curves from animals to man. We have too little knowledge of how man's lifestyle will affect the outcome.
The position is even more complicated. There is increasing awareness that electrophilic activation of carcinogens is not the only way they can be converted to active forms. Barrows and Shank (4) have recently demonstrated that the toxic effects of hydrazine, carbon tetrachloride, and similar chemicals on rat liver leads' to the formation of methylated DNA adducts and on replication to altered cells. Others have drawn attention to the possibility that free radical formation, peroxisome interaction, or superoxide formation rather than electrophilic activation of certain chemicals may modify DNA and lead to populations of changed cells.
Attempts to predict the shape of the tumor dose-response curve for a particular carcinogen in animals kept under defined conditions is a challenge still far beyond present scientific capabilities. Yet such information is a necessity for refinement of carcinogen regulation. One possibility that merits exploration at the chemical level is the measurement of DNA adduct or DNA damage after exposure to Carcinogens. This is achievable by the use of radiolabeled carcinogens or, in future, by the use of specially developed, highly specific monoclonal antibodies. This will clearly help to eliminate factors such as variations in metabolic activation and.in some conditions may serve as a possible numerical index of potential carcinogenicity in the population of cells that are altered by a carcinogen. I doubt very much if the survival competition phase of carcinogenesis is so simple that the level of DNA adduct formation will necessarily be linearly related to tumor incidence as suggested by Hoe1 et a1 (14). However, any simplification of the enormously complex problem would be welcome. There is no evidence that metabolic activation is the only doseresponse curve determinant in chemical carci nogcnes is. 1 2 8 CLAYSON TOXICOLOGIC PATHOLOGY 15.
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ical formation or peroxisome interaction. It's the concentration of the active moiety which arrives at the requisite ,part of the genome, probably the DNA. That, unfortunately, by current techniques is unmeasurable because these metabolites are so unstable that we don't have a chance to measure them. This could, of course, be influenced quite a lot by what is lying along the pathway between the point of metaboIite formation and the target. The next thing is-how are these other factors going to influence the major facets of the expression of the tumor or in the survival competition between tumor and normal cells? There I really can't help you, but I think it would be a n enormously complicated business. Our academic colleagues arc going to have to work this out for us.
DR. NEWBERNE: I think we have time for one or two more. Dr. Gibson? DR. GIBSON: If one were to be intelligent enough to separate a true carcinogen from promoters, among other things, would it be any easier to extrapolate and determine a dose-response curve than by the compounds which you have used this morning and which might not all be carcinogens in my opinion?
DR. CLAYSON: I think that's a very good question, Dr. Gibson. I think if we knew more about what was happening, we'd be able to make a lot more intelligent guesses or a lot more intelligent decisions on what is likely to happen. I have been trying to suggest this morning some of the ways which we might begin to think.
